Popovic, Miroslav (57213909443)Miroslav (57213909443)PopovicTerzic, Milan (55519713300)Milan (55519713300)TerzicDotlic, Jelena (6504769174)Jelena (6504769174)DotlicCeric-Banicevic, Arnela (57201660023)Arnela (57201660023)Ceric-Banicevic2025-07-022025-07-022017https://www.scopus.com/inward/record.uri?eid=2-s2.0-85045553395&partnerID=40&md5=47833d443dabed6d1c1bdbe51d5c3f4ehttps://remedy.med.bg.ac.rs/handle/123456789/13105Purpose: To evaluate the potential influence of clinical characteristics on survival of patients with advanced-stage of ovarian malignancies. Methods: The study included 163 women with FIGO stages 3 and 4 ovarian malignancies. Detailed history (family history of malignancies, age, menopausal status, body mass index (BMI), parity, comorbidities, symptoms/signs) was taken from all patients including tumor histopathological findings. Patients were postoperatively followed up to 5 years and adverse events were recorded. Univariate and multivariate survival analyses were applied. Results: Patient median survival was 22.77 months (range 1-91). Almost 74% of women survived in the first postoperative year, but only 12.9% had 5-year survival. In the postoperative period, each additional 6 months presented significant risk for unfavorable outcome. Women who were menopausal (p=0.033) and especially if older than 65 years (p=0.016) had worse prognosis. Patients with BMI ?25 kg/ m 2 had significantly longer postoperative survival (p=0.005; obesity hazard ratio/HR=1.525). Women with other gynecological or chronic illnesses had a significantly shorter postoperative survival (p=0.038; hazard ratio/HR=1.450). There were no significant differences in postoperative survival regarding patients’ parity, presence of symptoms or positive family history. Two significant models adjusted for FIGO stage (p=0.046) and histological tumor type (p=0.003) encompassing all assessed patient characteristics that could influence survival were obtained. Conclusions: The most important clinical characteristics that can be predictors of survival of patients with advanced ovarian malignancies are comorbidities and being overweight. © 2017 Zerbinis Publications. All rights reserved.Advanced stage ovarian carcinomaAgeBMIComorbiditiesHistorySurvival